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Abstract Objective To investigate the relationship
between the apolipoprotein E (APOE) gene and the risk of
mortality in normal weight, overweight and obese indi-
viduals. Methods and Results In a population-based study
of 7,983 individuals aged 55 years and older, we compared
the risks of all-cause and coronary heart disease (CHD)
mortality by APOE genotype, both overall and in sub-
groups deﬁned by body mass index (BMI). We found
signiﬁcant evidence for interaction between APOE and
BMI in relation to total cholesterol (p = 0.04) and HDL
cholesterol (p\0.001). Overall, APOE*2 carriers showed
a decreased risk of all-cause mortality. Analyses within
BMI strata showed a beneﬁcial effect of APOE*2o n l yi n
normal weight persons (adjusted hazard ratio (HR)
0.7[95% CI 0.5–0.9]). APOE*2 was not associated with a
lower risk of all-cause mortality in overweight or obese
persons. The effect of APOE*2 in normal weight individ-
uals tended to be due to the risk of CHD mortality (adjusted
HR 0.5 [95% CI 0.2–1.2]). Conclusion The APOE*2 allele
confers a lower risk of all-cause mortality only to normal
weight individuals.
Keywords APOE  BMI  Cholesterol  Mortality 
CHD mortality
Apolipoprotein E is a plasma protein involved in the
metabolism of cholesterol. The apolipoprotein E isoforms
e2, e3 and e4, determined by the three alleles of the apo-
lipoprotein E gene (APOE*2, APOE*3 and APOE*4),
differ in their binding afﬁnity to serum cholesterol and
hence in their ability to clear dietary fat from the blood [1].
Accordingly, total serum cholesterol levels differ between
APOE genotypes, with APOE*2 carriers having lower total
serum cholesterol levels and APOE*4 carriers having
higher levels than APOE*3 homozygotes [1–4].
In line with the clear differences in total serum choles-
terol levels associated with the APOE genotype, one would
expect that APOE*2 carriers have lower risks of cardio-
vascular morbidity and mortality and APOE*4 carriers
have higher risks. Yet, the evidence for this association is
inconsistent. A recent meta-analysis showed that APOE*4
was associated with a higher risk of coronary heart disease
(CHD), but found no association with APOE*2[ 5].
APOE*2 has been associated with a lower risk of mortality
[6] and APOE*4 with a higher risk [7–11], but also these
relationships were not found by others [12–19].
A possible explanation for these inconsistencies may be
found in the role of body weight. Several studies have
demonstrated that the relationship between the APOE gene
and lipids differs between normal weight, overweight and
obese individuals [20–22]. Total serum cholesterol levels
were higher among obese than among non-obese APOE*4
carriers [20], and obese APOE*2 carriers had higher serum
triglycerides and higher LDL-cholesterol levels than non-
obese APOE*2 carriers [20, 21]. While APOE*2 carriers
generally have the lowest cholesterol levels, those with
high BMI were found to have similar total serum choles-
terol levels compared to APOE*3 homozygotes and
APOE*4 carriers [20]. These ﬁndings suggest that the
adverse effects of high body weight may outweigh the
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DOI 10.1007/s10654-007-9202-6beneﬁcial effect of APOE*2 status. If so, a protective effect
of APOE*2 on mortality may be largest among normal
weight individuals.
Despite this evidence for a moderating effect of body
weight on the relation between the APOE gene and total
serum cholesterol, no studies so far have performed a
stratiﬁed analysis on the relationship between the APOE
gene and the risk of mortality. The aim of the present study
was to investigate the extent to which the relationship
between APOE genotypes and the risk of mortality differs
between normal weight, overweight and obese individuals.
We examined this relationship for both all-cause and CHD
mortality.
Methods
Study population and procedures
The present analyses were performed in the Rotterdam
Study, an ongoing population-based study on the determi-
nants of disease and disability among persons 55 years and
older. Details of this study have been described elsewhere
[23]. Baseline data were collected between 1990 and 1993.
During home visits, a trained investigator obtained infor-
mation on health status, medical history, medication use
and lifestyle. Subsequently, participants were invited to the
study center where they underwent an extensive clinical
examination. The Medical Ethics Committee of the Eras-
mus Medical Center approved the study protocol and all
participants provided written informed consent. From
10,275 eligible subjects, 7,983 (78%) individuals agreed to
participate in the study and were examined at baseline.
Data collection
Clinical and laboratory assessments
The clinical examination included weight, height, systolic
and diastolic blood pressure, serum glucose, total serum
cholesterol and high-density lipoprotein (HDL) cholesterol
levels. BMI was computed as weight (kg) divided by height
squared (m
2). Participants were classiﬁed as underweight
(BMI\18.5 kg/m
2), normal weight (18.5 kg/m
2 B
BMI\25 kg/m
2), overweight (25 kg/m
2 B BMI\30
kg/m
2) or obese (BMI C 30 kg/m
2)[ 24]. The waist and hip
circumferences were measured, and the waist-hip-ratio
(WHR) was calculated as indirect assessment of abdominal
fat. Systolic and diastolic blood pressures were measured
twice in a sitting position after 5 min rest using a random-
zero sphygmomanometer. The mean of the two measure-
ments was used for the analyses. Hypertension was deﬁned
as systolic blood pressure higher than 160 mmHg, diastolic
blood pressure higher than 100 mmHg, or the use of anti-
hypertensive medication indicated to treat high blood
pressure (hypertension grades 2 and 3) [25]. Diabetes was
diagnosed based on a random or post-load glucose level
higher than 11.0 mmol/l and/or the use of anti-diabetic
medication [26]. Total serum cholesterol and HDL-cho-
lesterol were measured using an automated enzymatic
procedure [27]. Hypercholesterolemia was deﬁned as a
total serum cholesterol level above 6.2 mmol/l [28]. The
APOE genotype was determined on DNA samples using a
polymerase chain reaction followed by enzymatic digestion
using methods previously described [29]. The frequencies
of APOE genotypes were APOE 2/2 0.8%, APOE 2/3
12.8%, APOE 2/4 2.7%, APOE 3/3 58.4%, APOE 3/4
22.9% and APOE 4/4 2.4%. The proportions of the APOE
alleles and genotypes were in Hardy-Weinberg equilibrium
(p = 0.71).
Mortality data
Information on the vital status of the participants was
obtained at regular intervals from the municipal population
registry. Causes of death were obtained from the general
practitioners by means of a standardized questionnaire
relating to the circumstances of death, most likely cause of
death and time and place of death. Two independent
research physicians coded all events according to the
International Classiﬁcation of Diseases, 10th edition (ICD-
10) [30]. CHD mortality was deﬁned as death from dis-
eases coded I20–I25, I46, I50 or R96. Mortality data were
available up to December 2003.
Statistical analyses
Of the 7,983 individuals who participated at baseline, 5,817
(73%) had APOE genotyped successfully and had complete
information on BMI, WHR and cholesterol levels. Because
persons with an extremely low BMI may suffer from life-
threatening diseases such as cancer, individuals with a BMI
below 18.5 kg/m
2 (n = 51) were excluded from the anal-
yses. Also, APOE 2/4 individuals were excluded from the
analyses (n = 158) to distinguish the effect of the APOE
alleles unambiguously. Hence, data from 5,608 participants
were available for the analyses.
Differences in baseline characteristics by APOE geno-
types were tested using the chi-squared statistic
(categorical variables) or ANOVA (continuous variables).
P for trend was obtained by testing the linearity of the sum
of squares from the ANOVA analyses. Multiple linear
regression analysis was used to assess the interaction
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123between APOE genotype and BMI on total serum choles-
terol and HDL-cholesterol levels. Differences in survival
probabilities were examined by comparing Kaplan-Meier
survival curves and tested using the log rank test. Kaplan-
Meier plots were constructed using age as the time scale to
take proper account of the effect of age [31, 32]. Risks of
mortality were quantiﬁed as hazard ratios (HRs) using Cox
proportional hazards analyses with age as the time scale.
The most common genotype (APOE 3/3) was used as the
reference category. The proportionality assumption of all
models was veriﬁed by testing the Schoenfeld residuals
[33]. Because the proportionality assumption was not met,
HRs were calculated for early and late mortality using
80 years as the cut-off age. This cut-off age was selected
because it led to proportionality of the models below and
above the cut-off age. HRs were calculated adjusted for
gender, smoking status, education level, total serum cho-
lesterol, HDL-cholesterol, waist to hip ratio hypertension
and diabetes mellitus.
Results
The mean age at entry was 68.7 years (SD = 8.7 years) and
41.8% of the participants were men. The mean follow up
time was 11.1 years (SD = 3.8 years). Baseline character-
istics of APOE*2 carriers, APOE*3 homozygotes and
APOE*4 carriers are presented in Table 1. As expected,
cholesterol levels differed signiﬁcantly between the geno-
type groups. The prevalence of hypercholesterolaemia was
lowest among APOE*2 carriers (49%) and highest among
APOE*4 carriers (66%). Furthermore, there were statisti-
cally signiﬁcant differences in BMI scores between the
genotype groups, with APOE*2 carriers having the highest
mean BMI (26.7 ± 3.6 kg/m
2) and APOE*4 carriers the
lowest (26.1 ± 3.4 kg/m
2). There were no statistically
signiﬁcant differences in WHR between the genotype
groups.
Figure 1 presents mean total serum cholesterol and
HDL-cholesterol levels by APOE genotype in normal
weight, overweight and obese persons. In all BMI strata,
APOE*2 carriers had the lowest and APOE*4 carriers the
highest total serum cholesterol (p for trend\0.01). The
association between HDL-cholesterol and APOE genotype
was in the opposite direction (p for trend\0.01). Note that
even though APOE*2 carriers had the lowest total serum
cholesterol levels in each BMI group, still 50% of the
overweight and 57% of the obese APOE*2 carriers had
hypercholesterolaemia compared to 41% of the normal
weight APOE*2 carriers (p = 0.003). There was no
Table 1 Baseline characteristics by APOE genotype groups
APOE*2 carriers APOE 3/3 APOE*4 carriers p
n 782 3,369 1,457
Sex (men) 38 42 42 0.05
Age at entry (years) 68.8 (8.8) 68.9 (8.7) 68.3 (8.5) 0.14
Body mass index (kg/m
2) 26.7 (3.6) 26.4 (3.6) 26.1 (3.4) \0.01
Normal weight 34 39 40
Overweight 49 47 47 \0.05
Obese 17 14 13
Waist-to-hip ratio 0.9 (0.1) 0.9 (0.1) 0.9 (0.1) 0.18
Systolic blood pressure (mmHg) 140 (22) 140 (23) 138 (2) 0.04
Diastolic blood pressure (mmHg) 74 (11) 74 (12) 73 (11) 0.06
Hypertension 36 34 33 0.25
Total serum cholesterol (mmol/l) 6.4 (1.3) 6.6 (1.2) 6.8 (1.2) \0.001
HDL-cholesterol (mmol/l) 1.4 (0.4) 1.3 (0.3) 1.3 (0.4) \0.001
Cholesterol lowering medication 3 2 3 0.71
Hypercholesterolemia 49 60 66 \0.001
Smoking status (current) 39 35 33 0.02
Education level
Lower 43 43 45
Intermediate 43 42 40 0.21
Higher 14 15 15
Diabetes mellitus 10 10 9 0.75
Values are means (standard deviations) for continuous variables and percentages for categorical variables. p values are obtained by ANOVA for
continuous variables and by v
2 for categorical variables
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123signiﬁcant evidence for interaction between APOE geno-
type and BMI in relation to total serum cholesterol
(p = 0.26) and HDL-cholesterol (p = 0.25). However,
when BMI was analyzed as a continuous trait, then the p
value for interaction was 0.04 for total serum cholesterol
and less than 0.001 for HDL-cholesterol.
A total of 1,918 deaths occurred during follow-up. Of
those, 257 occurred in 782 APOE*2 carriers (33%), 1,160
in 3,369 APOE*3 homozygotes (33%) and 501 in 1,457
APOE*4 carriers (34%). Differences between the Kaplan-
Meier survival curves of the APOE*2 carriers, APOE*3
homozygotes and APOE*4 carriers were small but statis-
tically signiﬁcant (p = 0.03) with APOE*2 carriers having
slightly lower mortality risks (Fig. 2). After adjustment for
other cardiovascular risk factors, APOE genotype was not
associated with all-cause mortality before or after 80 years
of age in the overall population (Table 2). The differences
between the curves were only statistically signiﬁcant in
normal weight individuals (p = 0.04; Fig. 3). Normal
weight carriers of the APOE*2 allele had a signiﬁcantly
lower risk of mortality before age 80 years (HR [95%
CI] = 0.7 [0.5–0.9]), but not after age 80 years (crude HR
[95% CI] = 1.0 [0.8–1.4]). There were no signiﬁcant dif-
ferences in the risk of mortality between genotype groups
among overweight or obese persons (Table 2).
To investigate whether the lower risk of mortality
observed among normal weight APOE*2 carriers was due
to a lower risk of mortality from CHD, we calculated the
HRs separately for CHD mortality. APOE genotype was
not signiﬁcantly associated with CHD mortality. Analysis
within BMI strata showed that normal weight APOE*2
carriers tended to have lower risks of CHD mortality
(adjusted HR [95% CI] = 0.5 [0.2–1.2]). No differences in
the risk of CHD mortality between genotype groups were
found in overweight or obese participants (Table 3).
Discussion
Our study shows that the APOE*2 allele has a protective
effect on overall mortality. This protective effect seems to
be limited to mortality from CHD. Analyses within BMI
strata demonstrated that this genetic advantage of APOE*2
was observed only in normal weight individuals, but not in
overweight and obese APOE*2 carriers.
The results of the present analyses may seem to contra-
dict our earlier work in this population. We previously
reported that the APOE gene was not signiﬁcantly related to
mortality [12]. While our ﬁndings come from the same
population, the mean follow-up time of the participants has
increased from 5.4 years to 11.1 years and the number of
deaths increased by 53% from 18% to 34%. This extended
follow-up has improved the statistical power of our study to
show a modest effect of APOE genotype on overall mor-
tality. Research on the relationship between APOE and
mortality has merely provided conﬂicting results [6–19,34].
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123Three out of eleven studies showed a protective effect of
APOE*2 [6, 14, 18]. and three a deleterious effect of
APOE*4 [8–10]. The latter effect may partly mediated by
the increased risk of Alzheimer disease in association with
APOE*4 and mortality [10, 11].
Note that our analysis showed small signiﬁcant
difference in the Kaplan-Meier survival curves, demon-
strating a protective effect of APOE*2 before age 80.
This may be due to the effect of age that becomes
apparent when performing survival analysis with age as
time scale, as we did in the present paper. Such ﬁnding is
compatible with previous reports suggesting that genes
affecting human lifespan might be age-speciﬁc [35].
Genetic and environmental interactions at older ages vary
from those at early ages and therefore explain the dif-
ferences in the association between APOE and mortality
before and after 80 years of age. A previous report
showed that among nonagenarians, APOE genotype has
no effect on cognitive function, cognitive decline or
survival [36].
In line with previous studies [20–22], we found that the
total serum cholesterol levels associated with APOE
genotype differed between normal weight, overweight and
obese individuals. As expected, mean levels of total serum
cholesterol increased with BMI and APOE*2 carriers had
the lowest mean total serum cholesterol in each BMI
group. APOE*4 carriers had higher cholesterol levels and
lower HDL-cholesterol concentrations than APOE*2
Table 2 Incidence rates and hazard ratios for all-cause mortality by APOE genotypes and BMI categories
Follow-up Incidence rate Hazard ratio Follow-up Incidence rate Hazard ratio
Deaths (py) Deaths/1,000 py (95% CI) (95% CI) Deaths (py) Deaths/1,000 py (95% CI) (95% CI)
Before 80 years of age After 80 years of age
All
APOE*2 carriers 101 6,782 14.9 (12.3–18.1) 0.9 (0.7–1.1) 156 21,764 7.2 (6.1–8.4) 0.9 (0.8–1.1)
APOE 3/3 481 28,703 16.8 (15.3–18.3) 679 95,808 7.1 (6.6–7.6)
APOE*4 carriers 198 12,693 15.6 (13.6–17.9) 1.0 (0.8–1.2) 303 41,637 7.3 (6.5–8.1) 1.2 (1.0–1.4)
Total 780 48,178 16.2 (15.1–17.4) 1,138 159,209 7.1 (6.7–7.6)
Normal weight
APOE*2 carriers 28 2,370 11.8 (8.2–17.1) 0.7 (0.5–0.9) 57 7,289 7.8 (6.0–10.1) 1.0 (0.8–1.4)
APOE 3/3 206 11,314 18.2 (15.9–20.9) 256 38,045 6.7 (6.0–7.6)
APOE*4 carriers 78 5,080 15.4 (12.3–19.2) 1.0 (0.7–1.3) 127 17,305 7.3 (6.2–8.7) 1.3 (0.9–1.7)
Total 312 18,764 16.6 (14.9–18.6) 440 62,639 7.0 (6.4–7.7)
Overweight
APOE*2 carriers 59 3,305 17.9 (13.8–23.0) 1.1 (0.9–1.5) 65 11,064 5.9 (4.6–7.5) 0.9 (0.7–1.1)
APOE 3/3 217 13,573 16.0 (14.0–18.3) 310 45,366 6.8 (6.1–7.6)
APOE*4 carriers 90 6,047 14.9 (12.1–18.3) 0.9 (0.7–1.2) 137 19,398 7.1 (6.0–8.4) 1.2 (1.0–1.5)
Total 366 22,924 16.0 (14.4–17.7) 512 75,827 6.8 (6.2–7.4)
Obese
APOE*2 carriers 14 1,107 12.6 (7.5–21.4) 1.0 (0.5–1.8) 34 3,411 10.0 (7.1–14.0) 1.0 (0.6–1.5)
APOE 3/3 58 3,816 15.2 (11.7–19.7) 113 12,398 9.1 (7.6–11.0)
APOE*4 carriers 30 1,566 19.2 (13.4–27.4) 1.3 (0.9–2.0) 39 4,934 7.9 (5.8–10.8) 1.1 (0.8–1.6)
Total 102 6,489 15.7 (12.9–19.1) 186 20,742 9.0 (7.8–10.4)
Hazard ratios adjusted for sex, waist-hip-ratio, smoking, education level, total serum cholesterol, HDL cholesterol hypertension and diabetes; py:
person-years; CI: Conﬁdence interval
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123carriers despite the presence of a lower BMI and equal
WHR. Previous reports showed that APOE genotype,
BMI and WHR determine together the lipid levels [20–
22, 37]. However, in our study abdominal fat, as mea-
sured by WHR, did not have any effect on the lipid levels
by APOE genotype, while BMI was an important deter-
minant. The signiﬁcant interaction between APOE
genotype and BMI in relation to total serum cholesterol
found previously [20], was also supported by this study.
Although the mechanism of such interaction has not been
yet elucidated, evidence suggests that obesity and
abdominal fat increase low density lipoprotein cholesterol
and therefore total cholesterol at a higher degree among
APOE*4 carriers [20–22, 37]. This is in line with our
observation that the deleterious effect of increased BMI
prevails over the beneﬁcial effects of the APOE*2 allele.
Furthermore, previous research in the Rotterdam Study
and the Dutch population indicated that among APOE*2
homozygous carriers, the expression of Hyperlipopro-
teinemia type III is determined to a great extent by
hyperinsulinemia and the presence of insulin resistance
syndrome [38], conferring and increased risk of CHD
through accelerated atherosclerosis [39].
Although the association between high BMI and high
cholesterol levels is well known and the APOE gene is
associated with cholesterol levels as previously described,
this is the ﬁrst study that examined the effect of APOE
genotype on mortality in BMI strata. We found that pres-
ence of the APOE*2 allele was associated with a decreased
risk of mortality only in normal weight individuals and that
this lower risk was partly explained by lower risk of CHD
mortality. These results were in line with the lower total
cholesterol and higher HDL levels among normal weight
APOE*2 carriers. Our ﬁnding that the protective effect of
APOE*2 was only found in normal weight individuals
suggests that the negative inﬂuences of increasing BMI
outweigh the positive effects of genetic predisposition.
When these results are conﬁrmed by other population-
based studies, a challenging question remains whether
weight loss in overweight and obese APOE*2 carriers
restores the genetic advantage of their APOE status.
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